image
PTC Therapeutics, Inc. PTCT
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 42.82
-0.971 %
$ 3.38 B
Market Cap
-9.05
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PTCT stock under the worst case scenario is HIDDEN Compared to the current market price of 42.8 USD, PTC Therapeutics, Inc. is HIDDEN

PTCT Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PTCT stock under the base case scenario is HIDDEN Compared to the current market price of 42.8 USD, PTC Therapeutics, Inc. is HIDDEN

PTCT Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PTCT stock under the best case scenario is HIDDEN Compared to the current market price of 42.8 USD, PTC Therapeutics, Inc. is HIDDEN

PTCT Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart PTCT

image
1M -33%
6M 16%
1Y 69%
3Y 8%
5Y -16%
All
$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
807 M REVENUE
-13.97%
Growth Rates
1Year -13.97%
3Years 14.42%
5Years 21.32%
7Years 22.55%
10Years 42.75%
-303 M OPERATING INCOME
13.40%
Growth Rates
1Year 13.40%
3Years 6.90%
5Years -9.43%
7Years -24.77%
10Years -11.77%
-363 M NET INCOME
42.02%
Growth Rates
1Year 42.02%
3Years 11.49%
5Years -7.63%
7Years -24.35%
10Years -14.51%
-108 M OPERATING CASH FLOW
32.02%
Growth Rates
1Year 32.02%
3Years 24.61%
5Years -1.77%
7Years -40.30%
10Years -6.52%
44.2 M INVESTING CASH FLOW
125.00%
Growth Rates
1Year 125.00%
3Years -41.37%
5Years 16.15%
7Years 18.94%
10Years 8.71%
256 M FINANCING CASH FLOW
-60.42%
Growth Rates
1Year -60.42%
3Years 130.56%
5Years -16.04%
7Years 28.50%
10Years 0.76%
213 M REVENUE
8.33%
Growth Rates
1Year -13.97%
3Years 14.42%
5Years 21.32%
7Years 22.55%
10Years 42.75%
-162 M OPERATING INCOME
-197.91%
Growth Rates
1Year 13.40%
3Years 6.90%
5Years -9.43%
7Years -24.77%
10Years -11.77%
-65.9 M NET INCOME
38.22%
Growth Rates
1Year 42.02%
3Years 11.49%
5Years -7.63%
7Years -24.35%
10Years -14.51%
-30 M OPERATING CASH FLOW
61.03%
Growth Rates
1Year 32.02%
3Years 24.61%
5Years -1.77%
7Years -40.30%
10Years -6.52%
268 M INVESTING CASH FLOW
727.33%
Growth Rates
1Year 125.00%
3Years -41.37%
5Years 16.15%
7Years 18.94%
10Years 8.71%
26.5 M FINANCING CASH FLOW
250.17%
Growth Rates
1Year -60.42%
3Years 130.56%
5Years -16.04%
7Years 28.50%
10Years 0.76%
Balance Sheet PTC Therapeutics, Inc.
image
Current Assets 1.37 B
Cash & Short-Term Investments 1.14 B
Receivables 159 M
Other Current Assets 67.3 M
Non-Current Assets 339 M
Long-Term Investments 0
PP&E 118 M
Other Non-Current Assets 222 M
66.84 %9.30 %3.95 %6.90 %13.01 %Total Assets$1.7b
Current Liabilities 581 M
Accounts Payable 17.3 M
Short-Term Debt 26.7 M
Other Current Liabilities 537 M
Non-Current Liabilities 2.22 B
Long-Term Debt 376 M
Other Non-Current Liabilities 1.85 B
19.16 %13.41 %65.86 %Total Liabilities$2.8b
EFFICIENCY
Earnings Waterfall PTC Therapeutics, Inc.
image
Revenue 807 M
Cost Of Revenue 0
Gross Profit 807 M
Operating Expenses 1.11 B
Operating Income -303 M
Other Expenses 60.7 M
Net Income -363 M
1b1b800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)807m0807m(1b)(303m)(61m)(363m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
Averages
1Year 100.00%
3Years 95.54%
5Years 95.13%
7Years 95.27%
10Years 49.10%
-37.50% OPERATING MARGIN
-37.50%
Averages
1Year -37.50%
3Years -45.90%
5Years -62.36%
7Years -59.76%
10Years -106.57%
-45.03% NET MARGIN
-45.03%
Averages
1Year -45.03%
3Years -63.95%
5Years -80.84%
7Years -76.36%
10Years -121.06%
33.08% ROE
33.08%
Averages
1Year 33.08%
3Years 90.23%
5Years -7250.57%
7Years -5190.24%
10Years -3655.81%
-21.31% ROA
-21.31%
Averages
1Year -21.31%
3Years -29.05%
5Years -26.80%
7Years -22.99%
10Years -28.02%
-26.31% ROIC
-26.31%
Averages
1Year -26.31%
3Years -26.28%
5Years -24.95%
7Years -21.58%
10Years -28.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis PTC Therapeutics, Inc.
image
00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -363 M
Depreciation & Amortization 75.7 M
Capital Expenditures -6.5 M
Stock-Based Compensation 74.6 M
Change in Working Capital 103 M
Others 153 M
Free Cash Flow -114 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets PTC Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for PTCT of $42.8 , with forecasts ranging from a low of $30 to a high of $58 .
PTCT Lowest Price Target Wall Street Target
30 USD -29.94%
PTCT Average Price Target Wall Street Target
42.8 USD -0.16%
PTCT Highest Price Target Wall Street Target
58 USD 35.45%
Price
Max Price Target
Min Price Target
Average Price Target
60605555505045454040353530302525May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership PTC Therapeutics, Inc.
image
Sold
0-3 MONTHS
6.92 M USD 9
3-6 MONTHS
12.2 M USD 7
6-9 MONTHS
0 USD 0
9-12 MONTHS
984 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,000 shares of its common stock and 28,220 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 35 new employees. prnewswire.com - 3 weeks ago
PTC Therapeutics says European Commission will remove muscle disorder drug PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug in January. reuters.com - 3 weeks ago
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe WARREN, N.J. , March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. prnewswire.com - 3 weeks ago
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies — Results show 97% of phenylalanine (Phe) tolerance study participants were able to increase their dietary Phe intake with a mean increase of 126% — — Genetic variant analysis of Phase 3 APHENITY trial demonstrates meaningful effect in classical subjects with non-BH4 responsive genotypes — WARREN, N.J. , March 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. prnewswire.com - 1 month ago
PTC Therapeutics: Upside In Rare Disease Innovation PTC Therapeutics is poised for a potential turnaround with key FDA reviews in 2025 for vatiquinone and sepiapterin, despite past revenue declines. The company maintains a strong cash position of over $2 billion, providing a buffer as it awaits regulatory approvals to boost revenue. PTC's diversified pipeline, including vatiquinone for Friedreich's ataxia, could significantly enhance revenue if approved, targeting a $2.8 billion market. seekingalpha.com - 1 month ago
PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Head of IR Matthew Klein - CEO Eric Pauwels - Chief Business Officer Pierre Gravier - CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph - JPMorgan Kelly Shi - Jefferies Tiago Fauth - Wells Fargo Eli Merle - UBS Gena Wang - Barclays Joel Beatty - Baird Sami Corwin - William Blair Peyton Bohnsack - TD Cowen Tazeen Ahmad - Bank of America Securities David Lebowitz - Citi Operator Ladies and gentlemen, thank you for standing by. Welcome to the PTC Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. seekingalpha.com - 1 month ago
PTC Therapeutics (PTCT) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 month ago
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates PTC Therapeutics (PTCT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $0.24 per share a year ago. zacks.com - 1 month ago
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results – Full year 2024 revenue of $807 million, exceeding guidance – – All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions, all of which were accepted for filing – – License and collaboration agreement with Novartis for PTC518 Huntington's disease program closed in January 2025 – – Cash of over $2.0 billion as of January 2025 – WARREN, N.J. , Feb. 27, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter ending December 31, 2024. prnewswire.com - 1 month ago
Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. zacks.com - 1 month ago
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
PTC Therapeutics to Participate in Upcoming Investor Conferences WARREN, N.J. , Feb. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: TD Cowen 45th Annual Health Care 2025 Conference   Tuesday, March 4 at 11:10 a.m. prnewswire.com - 1 month ago
8. Profile Summary

PTC Therapeutics, Inc. PTCT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.38 B
Dividend Yield 0.00%
Description PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Contact 100 Corporate Court, South Plainfield, NJ, 07080 https://www.ptcbio.com
IPO Date June 20, 2013
Employees 939
Officers Mr. Eric Pauwels Chief Business Officer Ms. Linda Montella Carter Senior Vice President & Chief Information Officer Dr. Matthew B. Klein F.A.C.S., M.D., M.S. Chief Executive Officer & Director Dr. Lee Golden M.D., Ph.D. Executive Vice President & Chief Medical Officer Dr. Neil Almstead Ph.D. Chief Technical Operations Officer Ms. Jane Baj Vice President of Corporate Communications Dr. Allan Steven Jacobson Ph.D. Co-Founder & Independent Director Mr. Pierre Gravier M.S. Chief Financial Officer Mr. Mark Elliott Boulding J.D. Executive Vice President & Chief Legal Officer Ms. Christine Utter CPA Senior Vice President, Chief Accounting Officer & Head of People Services